The neurologic side effects of chemotherapeutic agents

CONTINUUM Lifelong Learning in Neurology

Volumn 17, Issue 1, 2011, Pages 95-112

  Dropcho, Edward J ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; ALPHA INTERFERON; AMITRIPTYLINE; ANTIINFECTIVE AGENT; ASPARAGINASE; BEVACIZUMAB; BORTEZOMIB; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DOCETAXEL; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; INTERLEUKIN 2; LEVAMISOLE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PROCARBAZINE; RITUXIMAB; SURAMIN; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

ACUTE BRAIN DISEASE; ASEPTIC MENINGITIS; BRAIN DISEASE; BRAIN DYSFUNCTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LEUKOENCEPHALOPATHY; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RADICULOPATHY; REVIEW; SEIZURE; SPINAL CORD DISEASE; VEIN THROMBOSIS;

EID: 79957477202     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000394676.67372.87     Document Type: Review

References (42)

1. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82(2):291-294. (Pubitemid 30045372)
2. Rieger C, Fiegl M, Tischer J, et al. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004; 15(4):347-350. (Pubitemid 38526758)
3. Ziske CG, Schottker B, Gorschluter M, et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 2002;13(4):629-631. (Pubitemid 34461148)
4. Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109(8):3214-3218. (Pubitemid 46572506)
5. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon-alpha therapy. J Clin Oncol 2002;20(17):3703-3718. (Pubitemid 34983231)
6. Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005;104(10): 2222-2233. (Pubitemid 41579970)
7. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007;25(17):2455-2463. (Pubitemid 46999217)
8. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007;109(9):1905-1913. (Pubitemid 46668557)
9. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007;7(3):192-201.
10. Reddick WE, Shan ZY, Glass JO, et al. Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia. Cancer 2006;106(4): 941-949. (Pubitemid 43238463)
11. Oka M, Terae S, Kobayashi R, et al. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 2003;45(7):493-497. (Pubitemid 36944066)
12. Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005;62(10):1595-1600. (Pubitemid 41434567)
13. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004;62(3):451-456. (Pubitemid 38200859)
14. Linnebank M, Moskau S, Jurgens A, et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 2009;11(1):2-8.
15. Hook CC, Kimmel DW, Kvols LK, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992;31(3):262-267.
16. Videnovic A, Semenov I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology 2005;65(11):1792-1794.
17. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs. J Clin Oncol 1994;12(10):2216-2228.
18. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113(20):4834-4840.
19. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenisis agents. J Clin Oncol 2009;27(29):4865-4873.
20. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28): 4733-4740.
21. Karp BI, Yang JC, Khorsand M, et al. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 1996;47(2):417-424. (Pubitemid 26324037)
22. Haykin ME, Gorman M, van Hoff J, et al. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006;76(2):153-157. (Pubitemid 43125742)
23. Inaba H, Khan RB, Laningham FH, et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008;19(1):178-184.
24. Morris EB, Laningham FH, Sandlund JT, Khan RB. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer 2007;48(2):152-159. (Pubitemid 44958271)
25. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63(10):1475-1478. (Pubitemid 44547561)
26. Henderson RD, Rajah T, Nicol AJ, Read SJ. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology 2003;60(2):326-328. (Pubitemid 36152032)
27. Bleyer A, Choi M, Wang SJ, et al. Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53(7):1205-1210.
28. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12(3):210-215. (Pubitemid 47404378)
29. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60(2):337-340. (Pubitemid 36152036)
30. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8(1):10-16.
31. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130(4):1076-1088. (Pubitemid 47355585)
32. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29(3):387-392. (Pubitemid 38269758)
33. Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009;132(10):2712-2723.
34. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24(10):1633-1642. (Pubitemid 46638788)
35. Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J 2007;13(6):399-403.
36. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110(5):1042-1049. (Pubitemid 47312870)
37. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112(5):1593-1599.
38. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004;62(12):2291-2293. (Pubitemid 38787791)
39. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24(27):4507-4514. (Pubitemid 46630990)
40. Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44(11): 1507-1515.
41. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27(1): 127-145.
42. Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 2010;74(9):762-766.